Ensysce Biosciences (ENSCW) Operating Margin (2020 - 2025)
Ensysce Biosciences (ENSCW) reported Operating Margin of 758.68% for Q3 2025, down 77754.0% year-over-year from N/an in Q3 2024, and down 494.39% quarter-over-quarter from 127.64% in Q2 2025.
Ensysce Biosciences (ENSCW) Operating Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of Operating Margin data on file, last reported at 758.68% in Q3 2025.
- Operating Margin for Q3 2025 came in at 758.68%, down 77754.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 245.89% (down 10319.0% YoY), and the FY2024 annual result was 129.18%, up 35135.0% from the prior year.
- Operating Margin declined to 758.68% in Q3 2025 per ENSCW's latest filing, from 127.64% in the prior quarter.
- Over five years, Operating Margin peaked at 18.86% in Q3 2024 and troughed at 3400.56% in Q2 2022.
- A 5-year average of 719.09% and a median of 467.7% in 2023 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2023: Operating Margin tumbled 330774 bps in 2022, then surged 293286 bps in 2023.
- A 5-year view of Operating Margin shows it stood at 122.71% in 2021, then plunged by 253 bps to 432.57% in 2022, then tumbled by 42 bps to 612.72% in 2023, then surged by 55 bps to 274.34% in 2024, then sank by 177 bps to 758.68% in 2025.
- Business Quant data shows ENSCW's Operating Margin at 758.68% in Q3 2025, 127.64% in Q2 2025, and 149.08% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -758.68% |
| Jun 30, 2025 | -127.64% |
| Mar 31, 2025 | -149.08% |
| Dec 31, 2024 | -274.34% |
| Sep 30, 2024 | 18.86% |
| Jun 30, 2024 | -1,075.62% |
| Mar 31, 2024 | -602.82% |
| Dec 31, 2023 | -612.72% |
| Sep 30, 2023 | -621.83% |
| Jun 30, 2023 | -467.70% |
| Mar 31, 2023 | -324.36% |
| Dec 31, 2022 | -432.57% |
| Sep 30, 2022 | -2,206.30% |
| Jun 30, 2022 | -3,400.56% |
| Mar 31, 2022 | -796.36% |
| Dec 31, 2021 | -122.71% |
| Sep 30, 2021 | -1,406.28% |
| Jun 30, 2021 | -92.82% |
| Mar 31, 2021 | -209.23% |
| Dec 31, 2020 | -262.51% |